These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 15494358

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids.
    Quartuccio L, Soardo G, Romano G, Zaja F, Scott CA, De Marchi G, Fabris M, Ferraccioli G, De Vita S.
    Rheumatology (Oxford); 2006 Jul; 45(7):842-6. PubMed ID: 16418196
    [Abstract] [Full Text] [Related]

  • 4. Should rituximab be the rescue therapy for refractory mixed cryoglobulinemia associated with hepatitis C?
    Ahmed MS, Wong CF.
    J Nephrol; 2007 Jul; 20(3):350-6. PubMed ID: 17557269
    [Abstract] [Full Text] [Related]

  • 5. [Autoimmune and lymphoproliferative HCV-correlated manifestations: example of mixed cryoglobulinaemia (review)].
    Ghinoi A, Mascia MT, Puccini R, Ferri C.
    G Ital Nefrol; 2004 Jul; 21(3):225-37. PubMed ID: 15285001
    [Abstract] [Full Text] [Related]

  • 6. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature.
    Ferri C, Cacoub P, Mazzaro C, Roccatello D, Scaini P, Sebastiani M, Tavoni A, Zignego AL, De Vita S.
    Autoimmun Rev; 2011 Nov; 11(1):48-55. PubMed ID: 21821153
    [Abstract] [Full Text] [Related]

  • 7. Rituximab therapy for mixed cryoglobulinemia in seven renal transplant patients.
    Basse G, Ribes D, Kamar N, Mehrenberger M, Sallusto F, Esposito L, Guitard J, Lavayssière L, Oksman F, Durand D, Rostaing L.
    Transplant Proc; 2006 Sep; 38(7):2308-10. PubMed ID: 16980074
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
    Stasi R, Stipa E, Del Poeta G, Amadori S, Newland AC, Provan D.
    Rheumatology (Oxford); 2006 Nov; 45(11):1432-6. PubMed ID: 16632482
    [Abstract] [Full Text] [Related]

  • 10. Longterm course of mixed cryoglobulinemia in patients infected with hepatitis C virus.
    Sene D, Ghillani-Dalbin P, Thibault V, Guis L, Musset L, Duhaut P, Poynard T, Piette JC, Cacoub P.
    J Rheumatol; 2004 Nov; 31(11):2199-206. PubMed ID: 15517633
    [Abstract] [Full Text] [Related]

  • 11. Nail fold videocapillaroscopy in mixed cryoglobulinaemia.
    Rossi D, Mansouri M, Baldovino S, Gennaro M, Naretto C, Alpa M, Giachino O, Sena LM, Roccatello D.
    Nephrol Dial Transplant; 2004 Sep; 19(9):2245-9. PubMed ID: 15238627
    [Abstract] [Full Text] [Related]

  • 12. Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis.
    Sène D, Ghillani-Dalbin P, Amoura Z, Musset L, Cacoub P.
    Arthritis Rheum; 2009 Dec; 60(12):3848-55. PubMed ID: 19950292
    [Abstract] [Full Text] [Related]

  • 13. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
    Gellrich S, Muche JM, Wilks A, Jasch KC, Voit C, Fischer T, Audring H, Sterry W.
    Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
    [Abstract] [Full Text] [Related]

  • 14. T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy?
    Raynaud P, Caulet-Maugendre S, Foussard C, Salles G, Moreau A, Rossi JF, Patey M, Rousselet MC, Bene MC, Damotte D, Cornillet Lefebvre P, Martin A, Costes V, GOELAMS group.
    Hum Pathol; 2008 Feb; 39(2):194-200. PubMed ID: 17949786
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia.
    Lauria F, Lenoci M, Annino L, Raspadori D, Marotta G, Bocchia M, Forconi F, Gentili S, La Manda M, Marconcini S, Tozzi M, Baldini L, Zinzani PL, Foà R.
    Haematologica; 2001 Oct; 86(10):1046-50. PubMed ID: 11602410
    [Abstract] [Full Text] [Related]

  • 17. Experiences and problems pre-operative anti-CD20 monoclonal antibody infusion therapy with splenectomy and plasma exchange for ABO-incompatible living-donor liver transplantation.
    Usui M, Isaji S, Mizuno S, Sakurai H, Uemoto S.
    Clin Transplant; 2007 Oct; 21(1):24-31. PubMed ID: 17302588
    [Abstract] [Full Text] [Related]

  • 18. Rituximab for the treatment of glomerulonephritis in hepatitis C associated cryoglobulinaemia.
    Korte MR, van Heerde MJ, de Man RA, Betjes MH.
    Neth J Med; 2008 Jan; 66(1):27-30. PubMed ID: 18219065
    [Abstract] [Full Text] [Related]

  • 19. The B lymphocyte stimulator receptor-ligand system in hepatitis C virus-induced B cell clonal disorders.
    Landau DA, Rosenzwajg M, Saadoun D, Klatzmann D, Cacoub P.
    Ann Rheum Dis; 2009 Mar; 68(3):337-44. PubMed ID: 18434450
    [Abstract] [Full Text] [Related]

  • 20. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
    Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB, Andersen I, Schmidt K, Andersen TM, Peterslund NA, Birgens HS, Plesner T, Pedersen BB, Hasselbalch HC.
    Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.